No indication of increased infection rates using low ‐dose alemtuzumab instead of anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis before allogeneic stem cell transplantation

ConclusionWe saw no indication of increased infections rates when using low‐dose alemtuzumab as GvHD prophylaxis before allogeneic stem cell transplantation in this retrospective analysis.This article is protected by copyright. All rights reserved.

Source: Transplant Infectious Disease - November 27, 2017 Category: Transplant Surgery Authors: Thomas Neumann, Laila Schneidewind, Thomas Thiele, Daniel Pink, Meike Schulze, Christian Schmidt, William Kr üger Tags: Original Report Source Type: research